Tidal Investments LLC lifted its holdings in shares of DaVita Inc. (NYSE:DVA – Free Report) by 45.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,688 shares of the company’s stock after purchasing an additional 1,771 shares during the quarter. Tidal Investments LLC’s holdings in DaVita were worth $932,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Transcendent Capital Group LLC bought a new stake in DaVita during the third quarter worth approximately $25,000. Blue Trust Inc. grew its stake in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after buying an additional 78 shares during the last quarter. Family Firm Inc. bought a new position in DaVita in the 2nd quarter worth $43,000. Quarry LP acquired a new position in DaVita during the 3rd quarter worth $60,000. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of DaVita in the second quarter valued at about $68,000. Institutional investors own 90.12% of the company’s stock.
DaVita Stock Up 2.9 %
Shares of DVA stock opened at $151.85 on Friday. The stock has a market cap of $12.45 billion, a P/E ratio of 16.38, a price-to-earnings-growth ratio of 0.86 and a beta of 0.90. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The stock has a fifty day moving average price of $157.18 and a 200 day moving average price of $150.83. DaVita Inc. has a one year low of $103.40 and a one year high of $169.51.
Analysts Set New Price Targets
Several research firms recently weighed in on DVA. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Barclays raised their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $161.80.
Get Our Latest Research Report on DaVita
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
- Five stocks we like better than DaVita
- What Are Dividend Contenders? Investing in Dividend Contenders
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Stock Sentiment Analysis: How it Works
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- Golden Cross Stocks: Pattern, Examples and Charts
- 2 Underrated Quantum Computing Companies Starting to Rally
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.